Stapled Peptides: Bridging the Gap Between Small Molecules and Biologics in 2025
The Undruggable Proteome and the α-Helix Solution
An estimated 80% of disease-relevant protein-protein interactions (PPIs) remain inaccessible to conventional small molecule therapeutics (Verdine & Walensky, Clinical Cancer Research, 2007). These interfaces are typically large (1,500–3,000 Ų), flat, and lack the deep binding pockets that small molecules require. Peptides, which can mimic one face of the interaction, offer a natural solution — but linear peptides suffer from poor proteolytic stability, low membrane permeability, and conformational entropy penalties upon binding.
Hydrocarbon stapling, pioneered by Verdine and colleagues at Harvard, addresses these limitations by introducing an all-hydrocarbon cross-link between two non-natural amino acids positioned at i, i+4 (one helical turn) or i, i+7 (two helical turns) positions on the same face of an α-helix.
Biophysical Mechanism of Stapling
The stapling reaction employs olefin-bearing α,α-disubstituted amino acids (typically (S)-2-(4-pentenyl)alanine and (R)-2-(7-octenyl)alanine) that undergo ring-closing olefin metathesis (RCM) using Grubbs' second-generation ruthenium catalyst. The resulting macrocyclic constraint:
- Pre-organizes the α-helical conformation — reducing the entropic penalty of binding (ΔΔG ≈ 1–3 kcal/mol)
- Shields amide bonds from proteolytic cleavage — extending serum half-life 10–50× compared to linear counterparts (Bird et al., PNAS, 2010)
- Increases lipophilicity — the hydrocarbon bridge enhances passive membrane permeation, enabling access to intracellular targets
Circular dichroism (CD) spectroscopy typically shows an increase in helical content from ~20–40% (linear) to 70–95% (stapled), as measured by the characteristic double minima at 208 nm and 222 nm (Walensky et al., Science, 2004).
Clinical and Preclinical Programs
ALRN-6924 (Aileron Therapeutics)
The most advanced stapled peptide therapeutic is ALRN-6924, a dual inhibitor of MDM2 and MDMX that reactivates p53 tumor suppressor function. In Phase 1/2a trials for AML/MDS (NCT02909972), ALRN-6924 demonstrated:
- Dose-dependent p53 activation (confirmed by p21 induction in PBMCs)
- Clinical responses in TP53 wild-type patients
- Favorable safety profile with manageable GI toxicity
A myelopreservation study (NCT02264613) showed ALRN-6924 protects normal hematopoietic stem cells from chemotherapy-induced damage by activating p53-dependent cell cycle arrest — a first-in-class mechanism.
BCL-2 Family Targeting
The BH3 domain — a 16-residue α-helix — mediates critical interactions within the BCL-2 family of apoptosis regulators. Stapled BH3 peptides (SAHBs) have shown:
- Direct activation of BAX through binding to the α1/α6 trigger site (Gavathiotis et al., Nature, 2008)
- Inhibition of MCL-1, a key resistance mechanism in venetoclax-treated cancers
- In vivo efficacy in xenograft models at doses of 10–30 mg/kg IV
Emerging Targets
| Target PPI | Disease Area | Stage |
|---|---|---|
| p53-MDM2/MDMX | Oncology (AML, solid tumors) | Phase 2 |
| BCL-2/MCL-1 | Hematologic malignancies | Preclinical |
| β-catenin/TCF | Colorectal cancer (Wnt pathway) | Discovery |
| KRAS-effector | KRAS-driven cancers | Discovery |
| Estrogen receptor coactivator | Breast cancer | Preclinical |
| HIV-1 gp41 fusion | HIV entry inhibition | Preclinical |
Synthesis Challenges and Our Platform
Stapled peptide synthesis requires expertise in several non-standard techniques:
- Incorporation of α,α-disubstituted amino acids — sterically hindered coupling requiring extended reaction times and double-coupling protocols with HATU/HOAt activation
- On-resin RCM — typically performed in DCE with 20 mol% Grubbs' II catalyst at 40°C under microwave irradiation
- Stereochemical control — S₅ and R₈ configurations for i, i+7 staples must be precisely maintained
- Characterization — CD spectroscopy (helicity), HPLC (purity), MALDI-TOF MS (identity), and cell permeability assays (FITC-labeled analogs)
Boston Molecules' stapled peptide platform supports all three major stapling chemistries: olefin metathesis, lactam bridging (Lys-Asp/Glu side-chain cyclization), and CuAAC triazole stapling.
References
- Walensky, L.D. et al. “Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix.” Science 305, 1466–1470 (2004)
- Verdine, G.L. & Walensky, L.D. “The challenge of drugging undruggable targets in cancer.” Clinical Cancer Research 13, 7264–7270 (2007)
- Bird, G.H. et al. “Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic.” PNAS 107, 14093–14098 (2010)
- Gavathiotis, E. et al. “BAX activation is initiated at a novel interaction site.” Nature 455, 1076–1081 (2008)
Leave a Reply